What does this research mean for the field?

In patients with metastatic breast carcinoma, the FNC (fluorouracil, mitoxantrone, and cyclophosphamide) chemotherapy regimen provides similar efficacy and overall toxicity to the FEC (fluorouracil, epirubicin, and cyclophosphamide) regimen, but significantly reduces the incidence of alopecia. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To compare the efficacy and toxicity of two chemotherapy regimens in patients with metastatic breast carcinoma.

January 1, 1991Cancer Investigation

Combination Chemotherapy with Cyclophosphamide, Fluorouracil, and Either Epirubicin or Mitoxantrone: a Comparative Randomized Multicenter Study in Metastatic Breast Carcinoma

View Full Paper

Ask AI

Bookmark

Why the study?

Does FEC compared to FNC improve response rates in patients with advanced breast cancer?

Population

60 patients with advanced breast cancer and no prior chemotherapy for advanced disease

Comparison

Fluorouracil 500 mg/m2, epirubicin 50 mg/m2, and… vs Fluorouracil 500 mg/m2, mitoxantrone 10 mg/m2…

Design

RCT, Randomized

Authors

PPP PeritiNational Academies of Sciences, Engineering, and Medicine FPF PannutiANT Foundation Italy Onlus GCG. Robustelli della CunaUniversity of Parma

Discussion

Member takes

Implication

FEC does not improve response rates over FNC in advanced breast cancer; confirms comparable efficacy between regimens in this RCT.

Key Points

To compare the efficacy and toxicity of two chemotherapy regimens in patients with metastatic breast carcinoma.
Randomized multicenter trial involving 60 patients with advanced breast cancer
Patients received either fluorouracil, epirubicin, cyclophosphamide (FEC) or fluorouracil, mitoxantrone, cyclophosphamide (FNC) every 3 weeks
Evaluated response rates, duration, and toxicity measures
Response rates were 48.2% for FEC (CR 10.3%, PR 37.9%) and 40.7% for FNC (CR 3.7%, PR 37%), not significantly different (NS)
Median time to progression was 244 days for FEC and 86 days for FNC (NS)
Alopecia occurred in 80.6% of FEC patients compared to 44.8% of FNC patients (p<0.05)

Structured PICO

Does FEC compared to FNC improve response rates in patients with advanced breast cancer?

Population

60 patients with advanced breast cancer and no prior chemotherapy for advanced disease

Intervention

Fluorouracil 500 mg/m2, epirubicin 50 mg/m2, and cyclophosphamide 500 mg/m2 (FEC) i.v. Day 1 every 3 weeks

Comparator

Fluorouracil 500 mg/m2, mitoxantrone 10 mg/m2, and cyclophosphamide 500 mg/m2 (FNC) i.v. Day 1 every 3 weeks

Outcome

Response rate (complete response and partial response)surrogate

FEC and FNC regimens demonstrate similar efficacy in advanced breast cancer, but FNC is associated with significantly less alopecia.

Cite This Study

Periti et al. (1991) studied this question.

synapsesocial.com/papers/6a1bcd3c6f692abb725ee579 https://doi.org/10.3109/07357909109021321

View Full Paper

Ask AI

Bookmark

January 1, 1991Cancer Investigation

Combination Chemotherapy with Cyclophosphamide, Fluorouracil, and Either Epirubicin or Mitoxantrone: a Comparative Randomized Multicenter Study in Metastatic Breast Carcinoma

View Full Paper

Ask AI

Bookmark

Why the study?

Does FEC compared to FNC improve response rates in patients with advanced breast cancer?

Population

60 patients with advanced breast cancer and no prior chemotherapy for advanced disease

Comparison

Fluorouracil 500 mg/m2, epirubicin 50 mg/m2, and… vs Fluorouracil 500 mg/m2, mitoxantrone 10 mg/m2…

Design

RCT, Randomized

Authors

PPP PeritiNational Academies of Sciences, Engineering, and Medicine FPF PannutiANT Foundation Italy Onlus GCG. Robustelli della CunaUniversity of Parma

Discussion

Member takes

Implication

FEC does not improve response rates over FNC in advanced breast cancer; confirms comparable efficacy between regimens in this RCT.

Key Points

To compare the efficacy and toxicity of two chemotherapy regimens in patients with metastatic breast carcinoma.
Randomized multicenter trial involving 60 patients with advanced breast cancer
Patients received either fluorouracil, epirubicin, cyclophosphamide (FEC) or fluorouracil, mitoxantrone, cyclophosphamide (FNC) every 3 weeks
Evaluated response rates, duration, and toxicity measures
Response rates were 48.2% for FEC (CR 10.3%, PR 37.9%) and 40.7% for FNC (CR 3.7%, PR 37%), not significantly different (NS)
Median time to progression was 244 days for FEC and 86 days for FNC (NS)
Alopecia occurred in 80.6% of FEC patients compared to 44.8% of FNC patients (p<0.05)

Structured PICO

Does FEC compared to FNC improve response rates in patients with advanced breast cancer?

Population

60 patients with advanced breast cancer and no prior chemotherapy for advanced disease

Intervention

Fluorouracil 500 mg/m2, epirubicin 50 mg/m2, and cyclophosphamide 500 mg/m2 (FEC) i.v. Day 1 every 3 weeks

Comparator

Fluorouracil 500 mg/m2, mitoxantrone 10 mg/m2, and cyclophosphamide 500 mg/m2 (FNC) i.v. Day 1 every 3 weeks

Outcome

Response rate (complete response and partial response)surrogate

FEC and FNC regimens demonstrate similar efficacy in advanced breast cancer, but FNC is associated with significantly less alopecia.

Cite This Study

Periti et al. (1991) studied this question.

synapsesocial.com/papers/6a1bcd3c6f692abb725ee579 https://doi.org/10.3109/07357909109021321

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark